

AMENDMENTS TO THE SPECIFICATION:

Please amend the paragraph in the specification beginning on page 21, second full paragraph, with "As a model animal" to the following amended paragraph:

As a model animal, a nude rat implanted with human large cell lung carcinoma LC-6 [purchased from the Central Institute for Experimental Animals] was used. It is known that a nude rat implanted with human large cell lung carcinoma LC-6 shows an increased blood calcium level as increasing the tumor volume increases, and develops weight loss develops, and so on. After the development of hypercalcemia was confirmed, the model animal was repeatedly administered with elcatonin, which is a kind of calcitonin, until no amelioration in blood calcium level was observed, in other words ward, until the model animal acquired resistance to the calcitonin. In this manner, a calcitonin-resistant hypercalcemia model animal was produced. The human large cell lung carcinoma LC-6 was subcultured in vivo using a BALB/c-nu/nu nude mouse (CLEA Japan, Inc.).

Please amend the paragraph in the specification beginning on page 44, second full paragraph, with "As a result" to the following amended paragraph:

As a result, it was found that the chimeric antibodies had an ability to bind human PTHrP (1-34) and the cloned mouse antibody V-regions had the correct structures (FIG. 5). It was also found that there was no difference in the ability to bind PTHrP (1-34) between the chimeric antibody with L-chain λ chain C-region with the chimeric antibody with L-chain κ chain C-region. Therefore, the humanized antibody L-chain λ chain was used for construction of the L-chain C-region of the humanized antibody.

Please amend the paragraph in the specification beginning on page 62, second full paragraph, with “(ii-a) FR1,2/FR3,4 hybrid antibody” to the following amended paragraph:

(ii-a) FR1,2/FR3,4 hybrid antibody

When the L-chain was h/mMBC1L(λ), no antigen binding activity was observed. In contrast, when the L-chain was either m/hMBC1La λ or m/hMBC1Ld λ, the same level of antigen-binding activity as that of the chimeric #23-57-137-1 antibody was observed-(FIG. 7). These results suggest that FR3 and FR4 have no problem as humanized antibodies but FR1 and FR2 contain amino acid residue(s) that need to be replaced.

Please amend the paragraph in the specification beginning on page 62, third full paragraph, with “(ii-b) FR1/FR2 hybrid antibody” to the following amended paragraph:

(ii-b) FR1/FR2 hybrid antibody

When the L-chain was mhMBC1L (λ), no antigen binding activity was observed. In contrast, when the L-chain was hmmMBC1L (λ), the same level of antigen-binding activity as that of the chimeric #23-57-137-1 antibody was observed-(FIG. 8). These results suggest that FR1 has no problem as a humanized antibody but FR2 contains amino acid residue(s) that need to be replaced.